Cargando…

A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings

Objectives: HLD200, a once-daily, evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH), was designed to provide therapeutic effect beginning upon awakening and lasting into the evening. This pivotal, randomized, double-blind, multicenter, placebo-controlled, phase 3 trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Childress, Ann C., Cutler, Andrew J., Marraffino, Andrea, McDonnell, Mary Ann, Turnbow, John M., Brams, Matthew, DeSousa, Norberto J., Incledon, Bev, Sallee, Floyd R., Wigal, Sharon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041320/
https://www.ncbi.nlm.nih.gov/pubmed/31464511
http://dx.doi.org/10.1089/cap.2019.0070
_version_ 1783501137905713152
author Childress, Ann C.
Cutler, Andrew J.
Marraffino, Andrea
McDonnell, Mary Ann
Turnbow, John M.
Brams, Matthew
DeSousa, Norberto J.
Incledon, Bev
Sallee, Floyd R.
Wigal, Sharon B.
author_facet Childress, Ann C.
Cutler, Andrew J.
Marraffino, Andrea
McDonnell, Mary Ann
Turnbow, John M.
Brams, Matthew
DeSousa, Norberto J.
Incledon, Bev
Sallee, Floyd R.
Wigal, Sharon B.
author_sort Childress, Ann C.
collection PubMed
description Objectives: HLD200, a once-daily, evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH), was designed to provide therapeutic effect beginning upon awakening and lasting into the evening. This pivotal, randomized, double-blind, multicenter, placebo-controlled, phase 3 trial assessed improvements in functional impairment across the day using multiple validated measures tailored for different settings and time of day in children (6–12 years) with attention-deficit/hyperactivity disorder (ADHD). Methods: Following a 6-week, open-label titration of DR/ER-MPH to an optimal dose (20, 40, 60, 80, or 100 mg/day) and dosing time (8:00 PM ±1.5 hours), participants were randomized to treatment-optimized DR/ER-MPH or placebo for 1 week. The primary endpoint was the model-adjusted average of postdose Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale combined scores (SKAMP CS) over a 12-hour laboratory classroom day (8:00 AM to 8:00 PM). The key secondary endpoint was the Parent Rating of Evening and Morning Behavior-Revised, Morning (PREMB-R AM) subscale. Secondary/exploratory measures included the PREMB-R Evening (PREMB-R PM) subscale and Permanent Product Measure of Performance (Attempted [PERMP-A] and Correct [PERMP-C]). Safety endpoints included treatment-emergent adverse events (TEAEs). Results: After the treatment-optimization phase, the mean optimized dose was 66.2 mg and the most common prescribed dosing time was 8:00 PM. Double-blind DR/ER-MPH treatment significantly improved functional impairment versus placebo in the early morning (PREMB-R AM: p < 0.001), averaged over the classroom day (SKAMP CS: p < 0.001), and in the late afternoon/evening (PREMB-R PM: p = 0.003) in the intent-to-treat population (N = 117). Average PERMP-A (p = 0.006) and PERMP-C (p = 0.009) also indicated improved classroom performance with DR/ER-MPH versus placebo. In the double-blind phase, TEAEs did not differ between DR/ER-MPH and placebo groups and no serious TEAEs or TEAEs leading to discontinuation were reported. Conclusion: DR/ER-MPH was well tolerated and demonstrated significant improvements versus placebo in functional impairment throughout the day across different settings in children with ADHD.
format Online
Article
Text
id pubmed-7041320
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-70413202020-02-26 A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings Childress, Ann C. Cutler, Andrew J. Marraffino, Andrea McDonnell, Mary Ann Turnbow, John M. Brams, Matthew DeSousa, Norberto J. Incledon, Bev Sallee, Floyd R. Wigal, Sharon B. J Child Adolesc Psychopharmacol Original Articles Objectives: HLD200, a once-daily, evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH), was designed to provide therapeutic effect beginning upon awakening and lasting into the evening. This pivotal, randomized, double-blind, multicenter, placebo-controlled, phase 3 trial assessed improvements in functional impairment across the day using multiple validated measures tailored for different settings and time of day in children (6–12 years) with attention-deficit/hyperactivity disorder (ADHD). Methods: Following a 6-week, open-label titration of DR/ER-MPH to an optimal dose (20, 40, 60, 80, or 100 mg/day) and dosing time (8:00 PM ±1.5 hours), participants were randomized to treatment-optimized DR/ER-MPH or placebo for 1 week. The primary endpoint was the model-adjusted average of postdose Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale combined scores (SKAMP CS) over a 12-hour laboratory classroom day (8:00 AM to 8:00 PM). The key secondary endpoint was the Parent Rating of Evening and Morning Behavior-Revised, Morning (PREMB-R AM) subscale. Secondary/exploratory measures included the PREMB-R Evening (PREMB-R PM) subscale and Permanent Product Measure of Performance (Attempted [PERMP-A] and Correct [PERMP-C]). Safety endpoints included treatment-emergent adverse events (TEAEs). Results: After the treatment-optimization phase, the mean optimized dose was 66.2 mg and the most common prescribed dosing time was 8:00 PM. Double-blind DR/ER-MPH treatment significantly improved functional impairment versus placebo in the early morning (PREMB-R AM: p < 0.001), averaged over the classroom day (SKAMP CS: p < 0.001), and in the late afternoon/evening (PREMB-R PM: p = 0.003) in the intent-to-treat population (N = 117). Average PERMP-A (p = 0.006) and PERMP-C (p = 0.009) also indicated improved classroom performance with DR/ER-MPH versus placebo. In the double-blind phase, TEAEs did not differ between DR/ER-MPH and placebo groups and no serious TEAEs or TEAEs leading to discontinuation were reported. Conclusion: DR/ER-MPH was well tolerated and demonstrated significant improvements versus placebo in functional impairment throughout the day across different settings in children with ADHD. Mary Ann Liebert, Inc., publishers 2020-02-01 2020-01-30 /pmc/articles/PMC7041320/ /pubmed/31464511 http://dx.doi.org/10.1089/cap.2019.0070 Text en © Ann C. Childress et al. 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Childress, Ann C.
Cutler, Andrew J.
Marraffino, Andrea
McDonnell, Mary Ann
Turnbow, John M.
Brams, Matthew
DeSousa, Norberto J.
Incledon, Bev
Sallee, Floyd R.
Wigal, Sharon B.
A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings
title A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings
title_full A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings
title_fullStr A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings
title_full_unstemmed A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings
title_short A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings
title_sort randomized, double-blind, placebo-controlled study of hld200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and across settings
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041320/
https://www.ncbi.nlm.nih.gov/pubmed/31464511
http://dx.doi.org/10.1089/cap.2019.0070
work_keys_str_mv AT childressannc arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT cutlerandrewj arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT marraffinoandrea arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT mcdonnellmaryann arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT turnbowjohnm arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT bramsmatthew arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT desousanorbertoj arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT incledonbev arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT salleefloydr arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT wigalsharonb arandomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT childressannc randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT cutlerandrewj randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT marraffinoandrea randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT mcdonnellmaryann randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT turnbowjohnm randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT bramsmatthew randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT desousanorbertoj randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT incledonbev randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT salleefloydr randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings
AT wigalsharonb randomizeddoubleblindplacebocontrolledstudyofhld200adelayedreleaseandextendedreleasemethylphenidateinchildrenwithattentiondeficithyperactivitydisorderanevaluationofsafetyandefficacythroughoutthedayandacrosssettings